Relapsed or Refractory Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Relapsed or Refractory Colorectal Cancer Market Outlook

Thelansis’s “Relapsed or Refractory Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Colorectal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Relapsed or Refractory Colorectal Cancer Overview

Colorectal cancer, commonly known as colon cancer, primarily arises in the colon or rectum; it is the third most prevalent form of cancer known for its slow progression over many years. Typically, it originates as a non-malignant polyp, an unusual tissue growth lining the colon. There are three main presentations of colorectal cancer: sporadic (70%), familial clustering (20%), and inherited syndrome (10%). Various risk factors are linked to the development of colon cancer, including age, environmental factors, diets high in animal fat, obesity, smoking, excessive alcohol consumption, genetic predisposition, and a history of inflammatory bowel disease. The most prevalent type of colon cancer diagnosed in patients is adenocarcinoma. Colorectal cancer development hinges on the adenoma-carcinoma sequence, characterized by a gradual accumulation of genetic alterations. In sporadic colorectal cancers, the gatekeeper pathway, governed by a gene that regulates growth, accounts for roughly 85% of cases and is the primary mechanism of carcinogenesis in individuals with familial adenomatous polyposis (FAP). A pivotal step in this process involves mutating the tumor-suppressor gene APC. Furthermore, several other tumor-suppressor genes (such as DCC, DPC4/Smad4, nm32, and p53) and oncogenes (e.g., c-myc, c-neu, c-src, c-erb-2, and K-ras) also play significant roles. Less common types of colon cancer include carcinoid tumors (which originate in hormone-producing cells in the intestines), gastrointestinal stromal tumors (a form of soft tissue sarcoma), and lymphoma (related to autoimmune conditions and capable of originating in the colon).

• In 2023, it is anticipated that approximately 153,020 individuals in the United States will receive a colorectal cancer (CRC) diagnosis. Among this group, 19,550 individuals will be under the age of 50.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: